L
11.67
-0.39 (-3.23%)
| Penutupan Terdahulu | 12.06 |
| Buka | 11.90 |
| Jumlah Dagangan | 523,463 |
| Purata Dagangan (3B) | 1,112,277 |
| Modal Pasaran | 365,153,920 |
| Harga / Jualan (P/S) | 19.39 |
| Harga / Buku (P/B) | 1.96 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 Mar 2026 |
| EPS Cair (TTM) | 0.660 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.62% |
| Nisbah Semasa (MRQ) | 23.09 |
| Aliran Tunai Operasi (OCF TTM) | -51.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.56 M |
| Pulangan Atas Aset (ROA TTM) | -17.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -24.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | LENZ Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.13 |
|
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 2.76% |
| % Dimiliki oleh Institusi | 92.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Versant Venture Management, Llc | 31 Dec 2025 | 2,656,888 |
| 72 Investment Holdings, Llc | 31 Dec 2025 | 1,017,751 |
| Intrinsic Edge Capital Management Llc | 31 Dec 2025 | 569,705 |
| C Worldwide Group Holding A/S | 31 Dec 2025 | 500,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 Jan 2026 | Pengumuman | LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign |
| 14 Jan 2026 | Pengumuman | LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign |
| 07 Jan 2026 | Pengumuman | LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates |
| 05 Jan 2026 | Pengumuman | LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |